Adults: PO 1 to 2 g/day in single dose or 2 divided doses.
Children: PO 30 mg/kg/day in single dose or 2 divided doses.
Inhibits mucopeptide synthesis in bacterial cell wall.
Hypersensitivity to cephalosporins.
Use Cautiously in:
GI: Nausea; vomiting; diarrhea; anorexia; abdominal pain or cramps; flatulence; colitis, including pseudomembranous colitis.
GU: Pyuria; renal dysfunction; dysuria; reversible interstitial nephritis; hematuria; toxic nephropathy.
HEMA: Eosinophilia; neutropenia; lymphocytosis; leukocytosis; thrombocytopenia; decreased platelet function; anemia; aplastic anemia; hemorrhage.
HEPA: Hepatic dysfunction, abnormal LFT results.
OTHER: Hypersensitivity, including Stevens-Johnson syndrome, erythema multiforme and toxic epidermal necrolysis; serum sickness–like reactions (eg, skin rash, polyarthritis, arthralgia, fever); candidal overgrowth.
Inhibition of renal excretion of cefadroxil.
Therapeutic Classification: anti-infectives
Pharmacologic Classification: first generation cephalosporins
Absorption: Well absorbed after oral administration.
Distribution: Widely distributed. Crosses the placenta and enters breast milk in low concentrations. Minimal CSF penetration.
Metabolism/Excretion: Excreted almost entirely unchanged by the kidneys.
Half-life: 1–2 hr(increased in renal impairment).
Copyright ©Nims Drugs2015. All rights reserved.
Powered by : web creation Nepal